Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
Gabriel Hinojosa, PharmD, BCOP, reviews head-to-head comparisons in multiple myeloma regimens and evaluates efficacy and safety implications in treatment selection.
Gabriel Hinojosa, PharmD, BCOP, analyzes eligibility factors and treatment shifts in multiple myeloma care, considering autologous stem cell transplant risks and evolving therapy approaches with daratumumab.